Author's response to reviews

Title: Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

Authors:

Chandra P Belani (cbelani@psu.edu)
Nobuyuki Yamamoto (nbyamamo@wakayama-med.ac.jp)
Igor M Bondarenko (igor.bondarenko@rdp-ukraine.com)
Artem Poltoratskiy (1.5artem@gmail.com)
Silvia Novello (silvia.novello@unito.it)
Jie Tang (Jie.Tang@pfizer.com)
Paul Bycott (paul.bycott@pfizer.com)
Andreas G Niethammer (Andreas.Niethammer@pfizer.com)
Antonella Ingrosso (antonella.ingrosso@pfizer.com)
Sinil Kim (skim@mirmarx.com)
Giorgio V Scagliotti (scagliotti@ihnet.it)

Version: 4
Date: 16 April 2014

Author's response to reviews: see over
Dear Dr. Solera,

Re: Resubmission of the manuscript MS 7183263401163512

We are pleased to hear that our revised manuscript titled “Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer” is acceptable for publication as an original research article in *BMC Cancer*, provided we address two editorial revisions satisfactorily. First, we have uploaded the completed CONSORT checklist, as requested. Second, we have added the date of trial registry alongside the Trial Registration number in the abstract as requested, and uploaded the revised manuscript. We believe that we have responded to the two editorial requests appropriately and hope that the manuscript is now acceptable for publication in *BMC Cancer*.

Thank you for your consideration and we look forward to your response.

Sincerely yours,

Chandra P. Belani, MD
Penn State Hershey Cancer Institute
500 University Drive, CH72
Hershey, PA 17033
Tel: 717-531-1078
Fax: 717-531-0002
Email: cbelani@psu.edu